Healthcare professional network Doximity (NYSE:DOCS) will be announcing earnings results tomorrow afternoon. Here's what investors should know.
Last quarter Doximity reported revenues of $113.6 million, up 11.2% year on year, beating analyst revenue expectations by 4.1%. It was a very strong quarter for the company, with optimistic revenue guidance for the next quarter and a decent beat of analysts' revenue estimates.
Is Doximity buy or sell heading into the earnings? Find out by reading the original article on StockStory.
This quarter analysts are expecting Doximity's revenue to grow 10.6% year on year to $127.5 million, slowing down from the 17.8% year-over-year increase in revenue the company had recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.24 per share.
Majority of analysts covering the company have reconfirmed their estimates over the last thirty days, suggesting they are expecting the business to stay the course heading into the earnings. The company has a history of exceeding Wall St's expectations, beating revenue estimates every single time over the past two years on average by 3.7%.
Looking at Doximity's peers in the vertical software segment, some of them have already reported Q3 earnings results, giving us a hint of what we can expect. Agilysys (NASDAQ:AGYS) delivered top-line growth of 21.3% year on year, beating analyst estimates by 0.8% and PTC (NASDAQ:PTC) reported revenues up 18.1% year on year, exceeding estimates by 2.3%. Both stocks (Agilysys and PTC) traded flat on the results.
Read the full analysis of Agilysys's and PTC's results on StockStory.
There has been positive sentiment among investors in the vertical software segment, with the stocks up on average 4.1% over the last month. Doximity is down 4% during the same time, and is heading into the earnings with analyst price target of $28.2, compared to share price of $27.4.
The author has no position in any of the stocks mentioned.